Bedrijfsoverzicht
Psyence Biomedical Ltd. is a specialized entity within the healthcare sector, specifically operating in the biotechnology industry, where it focuses on the development of botanical psilocybin-based psychedelic medicines and the evaluation of natural psilocybin for treating adjustment disorder in patients with incurable cancer diagnoses under palliative care contexts. The company's operational scale is defined by a market capitalization of $6.12 million and a workforce consisting of 12 employees, reflecting the typical lean structure of early-stage biotechnology firms. Annual revenue figures are not disclosed in the current financial reports, which is common for companies in the research and development phase where capital allocation prioritizes clinical trials over commercial sales. This combination of a modest market cap and lack of reported revenue indicates that the company is positioned as a high-risk, high-potential venture seeking to validate its lead product candidate, P, before achieving commercial viability or generating significant sales volume.
Financiële gezondheid
The company reports a net income of $-3,941,597 and an EBITDA of $-4,145,455 for the trailing twelve months, while revenue and price-to-sales data are unavailable; the substantial gap between negligible reported revenue and significant net losses reveals a cost structure dominated by research, development, and operational expenses rather than commercial overhead. Free cash flow stands at $-4,006,023, indicating that the company is currently consuming cash reserves to fund its operations and product development initiatives rather than generating liquidity from sales. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which mathematically reflects the absence of revenue or the inability to calculate margins due to zero sales, rather than a standard operating loss percentage. The balance sheet holds $7.15 million in cash against $0 in debt, creating a net cash position that provides a substantial buffer for ongoing R&D expenditures without the burden of interest obligations. The debt-to-equity ratio is listed as N/A due to the lack of debt, confirming a capital structure that is entirely equity-financed and leveraged-free. Liquidity is robust with a current ratio of 8.09, suggesting the company possesses ample short-term assets to cover its current liabilities many times over, ensuring operational continuity despite cash burn. Return on Equity is -74.3% and Return on Assets is -34.4%, metrics that quantitatively demonstrate that management is currently utilizing shareholder capital and assets to generate losses, a typical characteristic of pre-revenue biotechs but one that signals negative immediate effectiveness in value creation.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both N/A, as the company reports a net loss, meaning these traditional multiples cannot be calculated; consequently, no comparison between trailing and forward expectations can be made based on earnings multiples. The price-to-book ratio is 0.07, indicating that the market values the company's equity at a fraction of its book value, which often occurs when assets are undervalued on the balance sheet or when the intangible value of intellectual property is not fully captured in historical cost accounting. Price-to-sales and EV/EBITDA metrics show a price-to-sales ratio as N/A due to missing revenue data, while the EV/EBITDA stands at 1.53, a metric that can be volatile for unprofitable firms but provides a relative measure of enterprise value against earnings power before interest, taxes, depreciation, and amortization. The stock's price range over the last 52 weeks spans from a low of $1.92 to a high of $468.36, illustrating extreme volatility; without a specific current price provided in the facts, the trading position relative to this range remains undefined, though the range itself highlights the speculative nature of the asset. The beta value is 0.31, which signifies that the stock's price volatility is significantly lower than that of the broader market, suggesting a defensive correlation or a lack of sensitivity to general market movements, potentially due to its small market cap and niche biotechnology focus.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of the pace at which earnings grow relative to revenue; however, the negative earnings growth implied by the net loss indicates that the company is not yet in a phase of profitable expansion. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings, which are currently negative, are theoretically retained if profitable, or cash is utilized for growth initiatives rather than distributed to shareholders. As a non-dividend payer, Psyence Biomedical Ltd. reinvests its limited financial resources entirely into the development of its psilocybin-based medicines and clinical evaluations rather than returning capital to investors. The overall growth and income profile is characterized by an absence of current revenue generation and dividend income, with the company relying on cash reserves to fuel future product development and potential future earnings once its lead product candidate achieves commercial success.